HERE
TO
HELP
INVESTMENT HIGHLIGHTS
First Mover Advantage
Post revenue with contract to provide DTx modules for a remote health service
Single solution for dual patient/provider markets
Leadership team with expertise in data science, life sciences and drug discovery and significant knowledge of formulation, commercialization and regulatory paths
INDUSTRY
Health tech, apps, platforms, software, mobile, sales and marketing, consumer electronics, data and analytics, digital therapeutics with AI
TARGET CONSUMER
New users; older population; security-driven customers with a mental health focus
MARKET SIZE
$238 billion on direct mental health care spend; $78 billion on opioid medication dosage abuse
WE ARE NEW PILL
NEW PILL is a health-tech, DTx + AI platform that unlocks the potential for proven therapeutics for mental health. Our patent pending technologies pave the way for personalized dosing and for tracking usage, adherence and efficacy data in real-time. It enables the use of legal cannabis, psychedelics and controlled drugs to improve mental health and overall well-being.
COMBINING TWO PRODUCTS INTO A SINGLE PLATFORM,
As a single platform, dual market solution for consumers that require help with self-care, as well a planned FDA- path for approved hardware/digital therapy designated specifically to treat mental health.
Combing two products into a single platform; one being consumer facing platform and the other, a FDA approved combo device for healthcare & clinics which focuses more heavily towards remote monitoring protocols including propriety datasets in efficacy reporting & usage data collection (PDR).
THE PROBLEM
With majority of doctors in America unaware of how to properly dose cannabis or psychedelics, so many patients and users are turning towards a plant based, alternative treatment path that is affordable. Depression is the #1 cause of disability in America. One-quarter of all people experience mental health issues and $238B on direct care spend has been attributed to their treatment--$40Bn & 8,000 deaths due primarily from medication errors or dosage errors alone, the overdose of opioids in the past 20 years according to CDC stands at 500k+ people in the US.
THE SOLUTION
NEW PILL's solution is a revolutionary platform that combines hardware, digital therapeutics software with AI dosing and propriety data. Our proprietary patent pending technology is a supporting layer for drug discovery companies, dispensaries and pharmacies to disrupt the Therapeutic & Self-Care Potential of Legal Cannabis and very promising future of Psychedelics for mental health treatments. In 2018 and 2019, FDA granted "Breakthrough Therapy" status for Psilocybin as a treatment for MDD. This is the missing link for drug discovery companies, providers and drug producers.
